Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio" - A multinational trial

BioFactors

Volumn 18, Issue 1-4, 2003, Pages 79-89

  Mortensen, Svend Aage ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

Clinical trials; Coenzyme Q10; Efficacy; Heart failure; Safety

Indexed keywords

ADENOSINE TRIPHOSPHATE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; LACTATE DEHYDROGENASE; PLACEBO; REACTIVE OXYGEN METABOLITE; UBIDECARENONE; DRUG DERIVATIVE; UBIQUINONE;

ANOREXIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENERGY METABOLISM; EPIGASTRIC PAIN; EXERCISE; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART MUSCLE METABOLISM; HOSPITALIZATION; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTICENTER STUDY; NAUSEA; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SYMPTOM; FORWARD HEART FAILURE; REVIEW; TREATMENT OUTCOME;

CARDIAC OUTPUT, LOW; CONTROLLED CLINICAL TRIALS; DOUBLE-BLIND METHOD; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; UBIQUINONE;

EID: 0346158465     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520180210     Document Type: Conference Paper

References (43)

1. E. Braunwald, ACE inhibitors - a cornerstone of the treatment of heart failure, New Engl J Med 325 (1991), 351-353.
2. M. Packer, Vasodilator and inotropic therapy for severe chronic heart failure: Passion and scepticism, JACC 2 (1983), 841-852.
3. ACC/AHA TASK FORCE REPORT, Guidelines for the evaluation and management of heart failure, JACC 26 (1995), 1376-1398.
4. 10 in human heart disease, Int J Vit Nutr Res 40 (1997), 380-390.
5. 10, Proc Natl Acad Sci USA 82 (1985), 901-904.
6. 10 therapy for idiopathic dilated cardiomyopathy, Am J Cardiol 65 (1990), 521-523.
7. 10: a new drug for cardiovascular disease, J Clin Pharmacol 30 (1990), 596-608.
8. 10 therapy: a major advance in the management of resistant myocardial failure, Drugs Exptl Clin Res 11 (1985), 581-593.
9. 10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure, Int J Tissue React 12 (1990), 155-162.
10. 10 withdrawal, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 5), K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, (1986), 281-290.
11. 10 withdrawal - clinical relapse in congestive heart failure, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 6), K. Folkers, G.P. Littarru and T. Yamagami, eds, Elsevier, Amsterdam, 1991, pp. 283-290.
12. 10 in primary heart failure, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 4), K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1984, pp. 353-367.
13. 10 treated congestive heart failure patients compared to conventionally treated patients, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 6), K. Folkers, G.P. Littarru and T. Yamagami, eds, Elsevier, Amsterdam, 1991, pp. 291-298.
14. 10, Int J Tissue React 12 (1990), 169-171.
15. 10 as adjunctive therapy in heart failure, Molec Aspects Med 15 (1994), s287-s294.
16. K. Folkers, T. Watanabe and M. Kaji, Critique of coenzyme Q in biochemical and biomedical research and in ten years of clinical research on cardiovascular disease, J Molecular Med 2 (1977), 431-460.
17. 10, Proc Natl Acad Sci USA 82 (1985), 4240-4244.
18. 10 in heart failure, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 5), K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1986, pp. 315-323.
19. 10 on patients with cardiac disease, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 5), K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1986, pp. 325-333.
20. 10 in ischemic cardiopathy, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 6), K. Folkers, G.P. Littarru and T. Yamagami, Elsevier, Amsterdam, 1991, pp. 321-326.
21. 10 in patients with moderate heart failure and chronic stable effort angina, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 6), K. Folkers, G.P. Littarru and T. Yamagami, Elsevier, Amsterdam, 1991, pp. 327-338.
22. 10 as an adjunctive in the treatment of chronic congestive heart failure, J Cardiac Failure 1 (1995), 101-107.
23. 10 (Ubichinon) bei der langzeitbehandlung der dilatativen kardiomyopathie, Z Kardiol 78 (1989), 360-365.
24. 10 therapy in patients with congestive heart failure: a long-term multicenter randomized study, Clin Investig 71 (1993), s134-s36.
25. 10 on left ventricular function in patients with dilative cardiomyopathy, Current Therapeutic Research 49 (1991), 878-886.
26. 10 treatment, Molec Aspects Med 15 (1994), s155-s163.
27. 10 on physical performance and recovery in myocardial failure, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 5), K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1986, pp. 371-377.
28. 10 Association, Boston, USA, 1998.
29. 10 treatment in serious heart failure, BioFactors 9 (1999), 285-289.
30. P.S. Watson, G.M. Scalia, A. Galbraith, D.J. Burstow and N. Bett, Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure, JACC 33 (1999), 1549-1552.
31. 10 in patients with congestive heart failure, Ann Intern Med 132 (2000), 636-640.
32. 10 as an adjunctive treatment of congestive heart failure, JACC 19 (1992), 216A.
33. 10 as an adjunctive therapy in patients with congestive heart failure, JACC 36 (2000), 304-305(letter).
34. 10 treatment of congestive heart failure: results of meta-analyses of controlled clinical trials, Ugeskr Læger 159 (1997), 7302-7308.
35. J.N. Townend and W.A. Littler, Angiotensin converting enzyme inhibitors in heart failure: how good are they? Br Heart J 69 (1993), 373-375.
36. 10 (Ubiquinone), Clin Investig 71 (1993), s116-s123.
37. 10 as adjunctive therapy in heart failure (interim analysis), Clinical Investig 71 (1993), s145-s149.
38. 10 and antioxidants in acute myocardial infarction, Molec Aspects Med 15 (1994), s143-s147.
39. 10 in patients with acute myocardial infarction, Cardiovasc Drugs Ther 12 (1998), 347-353.
40. M.R. Cowie and G.F. Mendez, BNP and congestive heart failure, Prog Cardiovasc Dis 44 (2002), 293-321.
41. 10, J Heart failure 1 (1993), s789A.
42. R. Ferrari, L. Agnoletti, L. Comini, G. Gaia, T. Bachetti, A. Cargnoni, C. Ceconi, S. Curello and O. Vissioli, Oxidative stress during myocardial ischemia and heart failure, Eur Heart J 19(Suppl B) (1998), B2-B11.
43. S.A. Mortensen, Overview of myocarditis, cardiotoxicity and metabolic aspects of myocardial diseases, in: Cardiology, S. Dalla Volta, A. Bayés de Luna, M. Brochier, F. Dienstl, V. Jezek, S.A. Mortensen, P.A. Poole-Wilson and E. Braunwald, eds, McGraw-Hill, Berkshire, England, chapter 46, 1999, pp. 545-561.